Establishing the clinical utility of epigenetic markers in cancer: many challenges ahead.
The use of epigenetic biomarkers in cancer management relies on the availability of robust assays and evidence that these markers are able to segregate clinically significant groups of patients. While many cancers are characterized by genetic and epigenetic modifications, it is far simpler to develop molecular tests that detect genetic rather than epigenetic changes. In this special report, we will describe the challenges associated with developing epigenetic assays and the practical issues that must be overcome before they can be used in the clinic.
Adult Cancer Program, Lowy Cancer Research Centre & Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales 2052, Australia.
Peter
P
Zarzour
Luke B
LB
Hesson
Robyn L
RL
Ward
D014408:Biomarkers, Tumor / Q000235:genetics; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D057890:Epigenomics; D006801:Humans; D009369:Neoplasms / Q000235:genetics
D014408:Biomarkers, Tumor